Avrobio Stock News

Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different

AVROBIO Inc (NASDAQ: AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition characterized by the accumulation of the amino acid

In the latest trading session, 5.01 million AVROBIO Inc. (NASDAQ:AVRO) shares changed hands as the company’s beta touched 1.62. With the company’s most recent per share price at $1.72 changed hands at -$0.04 or -2.56% at last look, the market valuation stands at $74.69M. AVRO’s current price is a discount, trading about -1058.14% off its … AVROBIO Inc. (NASDAQ: AVRO) Is Becoming An Interest-Losing Stock With A -2.56% Decline Read More »

Avrobio Inc''s (NASDAQ: AVRO ) gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. The data comes from a Phase 1/2 trial testing the safety and efficacy of AVR-RD-04 for cystinosis who had previously been given cysteamine, which is a standard treatment that reduces the buildup of cystine crystals in … Full story available on Benzinga.com

AVROBIO (AVRO) is trading ~11% higher in the pre-market on Wednesday after the company reported data from an ongoing Phase 1/2 clinical trial for AVR-RD-04 in adults…

Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. Get the Inside Access Traders Are Us

What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for February 9th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information |

The heavy selling pressure might have exhausted for AVROBIO, Inc. (AVRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analy

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc

AvroBio Inc (AVRO) shares closed today at 0.5% above its 52 week low of $2.11, giving the company a market cap of $92M. The stock is currently down 44.9% year-to-date, down 86.5% over the past 12 months, and down 93.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 142.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 2724.7% The company's stock price performance over the past 12 months lags the peer average by 180.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

AVROBIO, Inc. (AVRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estim

AvroBio Inc (AVRO) shares closed 1.3% lower than its previous 52 week low, giving the company a market cap of $99M. The stock is currently down 40.5% year-to-date, down 84.0% over the past 12 months, and down 92.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 234.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 5026.9% The company's stock price performance over the past 12 months lags the peer average by 175.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.